- Home
- TNMG vs CRBU Comparison
TNMG vs CRBU Comparison
Compare TNMG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNMG
- CRBU
- Stock Information
- Founded
- TNMG 2023
- CRBU 2011
- Country
- TNMG Japan
- CRBU United States
- Employees
- TNMG N/A
- CRBU N/A
- Industry
- TNMG
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- TNMG
- CRBU Health Care
- Exchange
- TNMG NYSE
- CRBU Nasdaq
- Market Cap
- TNMG 93.7M
- CRBU 93.0M
- IPO Year
- TNMG N/A
- CRBU 2021
- Fundamental
- Price
- TNMG $0.31
- CRBU $0.74
- Analyst Decision
- TNMG
- CRBU Strong Buy
- Analyst Count
- TNMG 0
- CRBU 5
- Target Price
- TNMG N/A
- CRBU $11.80
- AVG Volume (30 Days)
- TNMG 2.0M
- CRBU 1.1M
- Earning Date
- TNMG 01-01-0001
- CRBU 05-06-2025
- Dividend Yield
- TNMG N/A
- CRBU N/A
- EPS Growth
- TNMG N/A
- CRBU N/A
- EPS
- TNMG N/A
- CRBU N/A
- Revenue
- TNMG N/A
- CRBU $9,994,000.00
- Revenue This Year
- TNMG N/A
- CRBU N/A
- Revenue Next Year
- TNMG N/A
- CRBU $163.34
- P/E Ratio
- TNMG N/A
- CRBU N/A
- Revenue Growth
- TNMG N/A
- CRBU N/A
- 52 Week Low
- TNMG $0.35
- CRBU $0.66
- 52 Week High
- TNMG $34.08
- CRBU $4.21
- Technical
- Relative Strength Index (RSI)
- TNMG N/A
- CRBU 34.01
- Support Level
- TNMG N/A
- CRBU $0.71
- Resistance Level
- TNMG N/A
- CRBU $0.94
- Average True Range (ATR)
- TNMG 0.00
- CRBU 0.10
- MACD
- TNMG 0.00
- CRBU 0.00
- Stochastic Oscillator
- TNMG 0.00
- CRBU 23.44
About TNMG TNL MEDIAGENE
TNL Mediagene is a comprehensive media and data platform providing news and commentary on current events, business, technology, lifestyle and sports.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.